Statins are the mainstay in the pharmacological management of dyslipidemia. They may also have anti-inflammatory, anti-proliferative and anti-oxidative effects. Since they are widely prescribed, their safety remains an issue of concern. The major untoward effect of statins is myotoxicity, which ranges from mild to severe. In addition to inhibiting endogenous cholesterol synthesis, however, statins decrease coenzyme Q10 (CoQ10) synthesis, the decrease of which may be implicated in statin myotoxicity. Hence, the present study evaluated the effect of CoQ10 supplementation against simvastatin and atorvastatin induced myotoxicity, measuring creatinine phosphokinase (CPK), lactate dehydrogenase (LDH), myoglobin as well as K, creatinine and CoQ10 level along with histopathological determinants. Sprague-dawley adult male albino rats were orally administered simvastatin or atorvastatin (20, 80 mg day-1) for 3 months with concurrent oral CoQ10 (100 mg day-1) administration. Simvastatin or atorvastatin in the higher dose used caused significant elevation of CPK, LDH, K and myoglobin, depletion of CoQ10 level along with histological muscle damage. This was more evident with atorvastatin with respect to simvastatin. Concurrent administration of CoQ10 showed significant modulation of CPK, LDH, K and myoglobin concomitant to restoration of depleted CoQ10 level and improvement in histopathological muscle findings. Present findings demonstrate the protective effect of CoQ10 against myotoxicity of simvastatins and atorvastatin suggesting its use to avoid poor adherence to statin treatment and increase clinical benefit.